it also allows for predictions of tirzepatides eventual place in therapy - an agent used preferentially over GLP-1 RAs in patients with or without diabetes desiring to lose weight
After July 2021, more exposures were reported from health care facilities, and fewer calls originated from homes
The other 167 letters, the non-inspection-based warning letters, were issued pursuant to either a website, labeling, and/or promotional communications review (143 letters), a records request for remote evaluation of a facility under section 704(a)(4) of the FDCA (704(a)(4) request) (22 letters), 2 or a failure to register and list a product (electronic drug registration and listing system violations, eDRLS) (two letters)
By mimicking the GLP-1 hormone, the medication not only induces weight loss but also enhances insulin sensitivity and lowers blood glucose levels, effectively treating the underlying drivers of metabolic syndrome